Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)

被引：0
|
作者：
Santini, V. [1 ]
Silverman, L. [2 ]
Seymour, J. [3 ]
Fenaux, P. [4 ]
Mufti, G. [5 ]
Hellstrom-Lindberg, E. [6 ]
Sanz, G.
Finelli, C.
Backstom, J.
McKenzie, D.
Beach, C.
机构：
[1] Aou Careggi Univ Florence, UF Ematol, Florence, Italy
[2] Mt Sinai Sch Med, New York, NY USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Paris 13, Hop Avicenne, F-93430 Villetaneuse, France
[5] Kings Coll London, London, England
[6] Karolinska Univ Hosp, Stockholm, Sweden
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70208-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [31] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [32] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
    Zhou, C.
    Altorki, N.
    Vallieres, E.
    Felip, E.
    Zuo, Y.
    Howland, M.
    Xia, F.
    Hoang, T.
    Sandler, A.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter L.
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab
    Wilhelm, Francois
    Wilhelm, Isabelle E.
    Azarnia, Nozar
    Maniar, Manoj
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [34] Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment
    Lenz, Heinz-Josef
    Yoshino, Takayuki
    Argiles, Guillem
    Iveson, Timothy
    Sastre, Javier
    Harrison, Mark
    Lim, Howard John
    Tebbutt, Niall C.
    Peeters, Marc
    Satoh, Taroh
    Dittrich, Christian
    Sassi, Mouna
    Loembe, Arsene-Bienvenu
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [35] Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study
    Ye, Li
    Mei, Chen
    Ren, Yanling
    Zhou, Xinping
    Ma, Liya
    Xu, Weilai
    Wei, Juying
    Jiang, Huifang
    Zhang, Liming
    Zeng, Hui
    Tong, Hongyan
    JOURNAL OF CANCER, 2021, 12 (10): : 2975 - 2981
  • [36] Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.
    Ciuleanu, T.
    Samarzjia, M.
    Demidchik, Y.
    Beliakouski, V.
    Rancic, M.
    Bentsion, D. L.
    Orlov, S. V.
    Schaeffier, B. A.
    De Jager, R. L.
    Breitz, H. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [38] IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
    Altorki, N. K.
    Reck, M.
    Wakelee, H.
    Felip, E.
    Vallieres, E.
    Liersch, R.
    Oizumi, S.
    Tanaka, H.
    Novello, S.
    McCune, S.
    Li, H.
    Molinero, L.
    Mueller, S.
    Bennett, E.
    Gitlitz, B. J.
    McNally, V. A.
    Ballinger, M.
    Nabet, B.
    Srivastava, M. K.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S732 - S733
  • [39] The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
    Jonker, Derek J.
    Nott, Louise M.
    Yoshino, Takayuki
    Li, Chiang
    Gill, Shariene
    Shapiro, Jeremy David
    Ohtsu, Atsushl
    Zalcberg, John Raymond
    Vickers, Michael M.
    Slims, John
    Wei, Alice Chia-Chi
    Mittmann, Nicole
    Magoski, Nadine M.
    Murray, Yvonne
    Tsobanis, Eric
    Tu, Dongsheng
    Kerstein, David
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Shepherd, F
    Gralla, R
    Ramlau, R
    Mattson, K
    Bergman, B
    Kraszko, P
    Rudd, R
    Berille, J
    Kim, Y
    Coughllin, S
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S247 - S247
12345